Patents Assigned to APOGENIX AG
  • Light single-chain fusion polypeptides, encoding nucleic acid molecules and host cells
    Patent number: 11214605
    Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: January 4, 2022
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) receptor agonist proteins
    Patent number: 11149075
    Abstract: Provided herein are specific GITR receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a GITRL-associated disease or disorder. The GITR receptor agonist proteins provided herein comprise three soluble GITRL domains and an Fc fragment. The GITR receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: October 19, 2021
    Assignee: APOGENIX AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
  • Monoclonal anti-CD95L (cluster of differentiation 95 ligand) antibody
    Patent number: 11014991
    Abstract: The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: May 25, 2021
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Jaromir Sykora, Christian Merz, Tim Schnyder, Harald Fricke
  • Single-chain CD137-receptor agonist proteins
    Patent number: 10870688
    Abstract: Provided herein are specific CD137 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD137L-associated disease or disorder. The CD137 receptor agonist proteins provided herein comprise three soluble CD137L domains and an Fe fragment. The CD137 receptor agonist proteins are substantially non-aggregating and suitable for therapeuctic, diagnostic and/or research applications.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: December 22, 2020
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
  • Single-chain CD27-receptor agonist proteins
    Patent number: 10844108
    Abstract: Provided herein are specific CD27 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD27L-associated disease or disorder. The CD27 receptor agonist proteins provided herein comprise three soluble CD27L domains an and Fc fragment. The CD27 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: November 24, 2020
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
  • Single-chain CD40-receptor agonist proteins
    Patent number: 10793616
    Abstract: Provided herein are specific CD40 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD40L-associated disease or disorder. The CD40 receptor agonist proteins provided herein comprise three soluble CD40L domains and an Fc fragment. The CD40 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: October 6, 2020
    Assignee: Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Tim Schnyder
  • Single-chain light receptor agonist proteins
    Patent number: 10683332
    Abstract: Provided herein are specific LIGHT receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a LIGHT-associated disease or disorder. The LIGHT receptor agonist proteins provided herein comprise three soluble LIGHT domains and an Fc fragment. The LIGHT receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 16, 2020
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
  • Single-chain TL1A receptor agonist proteins
    Patent number: 10683338
    Abstract: Provided herein are specific TL1A receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TL1A-associated disease or disorder. The TL1A receptor agonist proteins provided herein comprise three soluble TL1A domains and an Fc fragment. The TL1A receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 16, 2020
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
  • CD27 ligand (CD27L) single-chain fusion polypeptides
    Patent number: 10640543
    Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: May 5, 2020
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • Single-chain glucocorticoid-induced tumor necrosis factor receptor (GITR) agonist proteins
    Patent number: 10533043
    Abstract: Provided herein are specific GITR receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a GITRL-associated disease or disorder. The GITR receptor agonist proteins provided herein comprise three soluble GITRL domains and an Fc fragment. The GITR receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: January 14, 2020
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
  • CD40L single-chain fusion polypeptides and encoding nucleic acids
    Patent number: 10519208
    Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 31, 2019
    Assignee: Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • CD27L collectin fusion proteins and encoding nucleic acids
    Patent number: 10519217
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: December 31, 2019
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschaedel
  • Monoclonal anti-CD95L antibody
    Patent number: 10428154
    Abstract: The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: October 1, 2019
    Assignee: Apogenix AG
    Inventors: Christian Gieffers, Oliver Hill, Meinolf Thiemann, Jaromir Sykora, Christian Merz, Tim Schnyder, Harald Fricke
  • Nucleic acids encoding artificial signal peptides and methods of production thereof
    Patent number: 10370441
    Abstract: The present invention relates to an isolated fusion protein comprising an extracellular CD95 domain or a functional fragment thereof and an Fc domain or functional fragment thereof, formulations providing such fusion protein in a stable form as well as a method for producing such a fusion protein.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: August 6, 2019
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • Diagnostic anti-CD95L antibody
    Patent number: 10266600
    Abstract: The present invention relates to a specific CD95L antibody and to the use thereof in the diagnosis of a cancer disease.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: April 23, 2019
    Assignee: APOGENIX AG
    Inventors: Harald Fricke, Christian Gieffers, Jaromir Sykora
  • Glucocorticoid-induced tumor necrosis factor receptor ligand (GITRL) single-chain fusion polypeptides
    Patent number: 10118953
    Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: November 6, 2018
    Assignee: APOGENIX AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • GITRL-collectin fusion proteins and encoding nucleic acids
    Patent number: 10000550
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: June 19, 2018
    Assignee: Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
  • Artificial signal peptide
    Patent number: 9908928
    Abstract: The present invention relates to an isolated fusion protein comprising an extracellular CD95 domain or a functional fragment thereof and an Fc domain or functional fragment thereof, formulations providing such fusion protein in a stable form as well as a method for producing such a fusion protein.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: March 6, 2018
    Assignee: Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • Single-chain trail-receptor agonist proteins
    Patent number: 9908927
    Abstract: Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The TRAIL receptor agonist proteins provided herein comprise three soluble TRAIL domains and an Fc fragment. The TRAIL receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: March 6, 2018
    Assignees: AbbVie Inc., Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Fritz G. Buchanan, Darren C. Phillips, Susan E. Lappe
  • CD27 single chain molecules and encoding nucleic acids
    Patent number: 9725495
    Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: August 8, 2017
    Assignee: Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann